IL25 and idiopathic pulmonary fibrosis: Interestingly, we demonstrated that significant changes in IL-25 and TSLP EBC levels before and after 12 months of antifibrotic therapy were observed in the subgroup of IPF patients treated with pirfenidone, but not in the subgroup of patients treated with nintedanib.